Product Description
VGB-R04 is a novel AAV vector carrying a high specific activity factor IX variant. For Hemophilia B (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05152732)
Mechanisms of Action: Gene Therapy, FIX
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Institute of Hematology & Blood Diseases Hospital, China
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hemophilia B|Hemophilia A
Phase 1: Hemophilia A|Hemophilia B
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20221462 |
CTR20221462 | N/A |
Terminated |
Hemophilia B |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
NCT05152732 |
VGB-R04-001 | P1 |
Recruiting |
Hemophilia B|Hemophilia A |
2025-03-01 |
2023-09-19 |
Primary Endpoints|Treatments |
|
NCT05441553 |
VGB-R04-101 | P2 |
Unknown status |
Hemophilia B|Hemophilia A |
2025-01-01 |
28% |
2025-01-03 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|